ONCOC4
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment. OncoC4 was founded in 2020 and was headquartered in Rockville, Maryland.
ONCOC4
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2020-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.oncoc4.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Similar Organizations
Fedora Pharmaceuticals
Fedora Pharmaceuticals engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs.
GlycoDesign
GlycoDesign is a biopharmaceutical company, engages in the discovery and development of proprietary drugs for the treatment.
Current Employees Featured
Official Site Inspections
http://www.oncoc4.com Semrush global rank: 5.64 M Semrush visits lastest month: 1.49 K
- Host name: oncoc4.tempurl.host
- IP address: 144.202.19.82
- Location: Atlanta United States
- Latitude: 33.7838
- Longitude: -84.4455
- Metro Code: 524
- Timezone: America/New_York
- Postal: 30318
More informations about "OncoC4"
Next-generation therapies for hard-to-treat cancers | OncoC4
From pioneering research to developing next-generation therapeutics, we are poised to make cancer therapies safer, more effective, and more durable. A new and enduring generation of …See details»
OncoC4 - Home
From Scientific Discoveries to Novel Therapeutics. We are a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of …See details»
About OncoC4 | Meet our world-class team of experts
Anchored by a team of business strategists and operations leaders with a proven history of getting products through clinical development, we are poised to offer patients battling evasive cancers …See details»
OncoC4 - Crunchbase Company Profile & Funding
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment. View contacts for OncoC4 to access new leads and connect with decision-makers.See details»
OncoC4, Inc. - LinkedIn
Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer.See details»
OncoC4 - Contacts, Employees, Board Members, Advisors
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment. ... Products. Resources. Pricing. Resources. Log In. …See details»
OncoC4, Inc. - Drug pipelines, Patents, Clinical trials
Dr. Wakelee is a world-renowned expert in the research and treatment of lung cancerOncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and immunotherapy ROCKVILLE, Md., …See details»
BioNTech signs deal to co-develop OncoC4's cancer drug
March 20 (Reuters) - Germany's BioNTech SE , opens new tab said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialize its cancer antibody drug candidate.See details»
BioNTech and OncoC4 Announce Strategic Collaboration to Co …
Mar 20, 2023 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial …See details»
OncoC4 takes its Siglec-10 bet into the clinic - ApexOnco
Jan 24, 2024 In the case of OncoC4, Siglec-10 is an extremely unusual industry target, but remarkably ONC-841 isn’t the company’s only shot at this goal: its pipeline reveals four other anti-Siglec-10 projects. These include a Car-T …See details»
BioNTech's OncoC4 partnership off to good start with …
Jun 2, 2023 BioNTech and OncoC4's drug is a so-called anti-CTLA-4 antibody, the same immunotherapy drug class as AstraZeneca's Imjudo, opens new tab, or tremelimumab, which won its first approval last October ...See details»
BioNTech and OncoC4 Announce Strategic Collaboration to Co …
Mar 20, 2023 BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial …See details»
Treating the most resistant cancers | OncoC4 pipeline
Diverse tumors demand a diverse arsenal of therapeutic approaches. From monoclonal and bispecific antibodies, to antibody drug conjugates, to CAR T-cell therapies, discover what we …See details»
OncoC4 Announces FDA Clearance of IND Application for
2 days ago OncoC4 Announces FDA Clearance of IND Application for Potential Best-in-Class PD-1/VEGF Bispecific AI-081 in Advanced Solid Tumors. December 02, 2024 08:00 ET | …See details»
OncoC4 founders take own science under their wing in new …
Sep 25, 2024 OncoC4 is a spinout from Liu- and Zheng-founded OncoImmune, which was acquired in 2020 by Merck & Co. for $425 million. Now, the private, Maryland-based biotech is …See details»
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE …
ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the …See details»
Information on pipeline updates and partnerships | OncoC4 news
Oct 1, 2024 ROCKVILLE, Maryland, USA, August 30, 2024 — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer and […] Read more. …See details»
OncoC4 to Present Positive Data from Ongoing Phase 1/2
Nov 7, 2022 OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022 November 07, 2022 08:00 ET | …See details»
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase …
Dec 30, 2022 The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial ONC-392 is the …See details»
Driving innovation in cancer care | Careers at OncoC4
OncoC4 is currently recruiting for the following positions: In house Clinical Research Associate (In-house CRA) Senior Clinical Research Associate – Midwest Senior Clinical Research …See details»